CD69: a Classical Early Marker of Lymphocyte Activation, a Pivotal Regulator of Hematologic Diseases and Autoimmune Disorders!

CD69: a Classical Early Marker of Lymphocyte Activation, a Pivotal Regulator of Hematologic Diseases and Autoimmune Disorders!

CD69, also known as AIM, EA-1, Leu23, and MLR-3, is a type II transmembrane glycoprotein. In the case of T cell activation, CD69 is one of several representative molecules, including IL-2 receptor CD25 and transferrin receptor CD71. Studies have shown that CD69+T cells accompanied by IL-12β, IL-18α, and IL-16β mRNA levels increase, promotes interferon-γ (IFN-γ) production. Albeit recent studies have revealed potential CD69 ligands (such as Gla-1 and S1PR1), the biological functions and mechanism of CD69 remains to be further explored (Click to Read More about CD69).

Clinical trials suggested that GeneFrontier Corp. is developing a monoclonal antibody drug (GFC-101) that targets CD69 and shows promise for treating conditions such as irritable bowel syndrome, rheumatoid arthritis, and respiratory disorders. Other drugs or antibodies targeting CD69 expression are being investigated, including in the treatment of Chronic Lymphocytic Leukemia (CLL). As further research is conducted on CD69, it is anticipated that innovative immunotherapeutic therapies aimed at CD69 will emerge.

To fully support researchers and pharmaceutical companies in their research on CD69 in hematological and autoimmune disorders, CUSABIO presents CD69 active proteins (CSB-MP004952HU and CSB-EP004952HU-B) to support your research on the mechanism of CD69 or its potential clinical value (click for the full list of CD69 products: CD69 Proteins; CD69 antibodies).

CD69 proteins: Recombinant Human Early activation antigen CD69(CD69),partial (Active) Recombinant Human Early activation antigen CD69(Cd69),partial,Biotinylated High Purity Validated by SDS-PAGE Excellent Bioactivity Validated by Functional ELISA High Purity Validated by SDS-PAGE The purity was greater than 96.7% as determined by SDS-PAGE. (Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel. Immobilized Human CD69 at 2μg/mL can bind Anti-CD69 recombinant antibody (CSB-RA004952MA1HU), the EC50 is 23.17-26.04 ng/mL The purity was greater than 90% as determined by SDS-PAGE.(Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel. CD69 Antibody & Stable Transfer Cell Line: CD69 Antibody CSB-PA001473 CD69 Antibody CSB-PA005841 CHOK1/Human CD69 Stable Cell Line CSB-SC004952HU2

CUSABIO appreciates the critical role that you and our products play in research since many scientists are diligently pursuing their research to further scientific innovation and discovery. Our customer service and technical support teams are equipped to remain available to help with your research needs and answer any questions.